Belite Bio, Inc. Files 20-F Annual Report for Fiscal Year Ended December 31, 2023

Ticker: BLTE · Form: 20-F · Filed: Mar 12, 2024 · CIK: 1889109

Belite Bio, INC 20-F Filing Summary
FieldDetail
CompanyBelite Bio, INC (BLTE)
Form Type20-F
Filed DateMar 12, 2024
Risk Levelmedium
Pages15
Reading Time18 min
Key Dollar Amounts$0.0001, $, $1, $1.00
Sentimentneutral

Sentiment: neutral

Topics: Belite Bio, 20-F Filing, Annual Report, Biotechnology, Financial Disclosure

TL;DR

<b>Belite Bio, Inc. has submitted its 20-F annual report detailing its financial performance and corporate activities for the fiscal year ending December 31, 2023.</b>

AI Summary

BELITE BIO, INC (BLTE) filed a Foreign Annual Report (20-F) with the SEC on March 12, 2024. Belite Bio, Inc. filed its 20-F annual report for the fiscal year ending December 31, 2023. The filing includes financial data and disclosures relevant to U.S. GAAP. Key dates related to warrant valuations and stock offerings are noted, including June 2, 2023, and April 28, 2022. The company's fiscal year ends on December 31st. Belite Bio, Inc. is classified under Pharmaceutical Preparations (SIC 2834).

Why It Matters

For investors and stakeholders tracking BELITE BIO, INC, this filing contains several important signals. This 20-F filing provides a comprehensive overview of Belite Bio's financial health and operational status for the past fiscal year, crucial for investors assessing the company's trajectory. The detailed disclosures within the 20-F are essential for understanding the company's financial instruments, such as warrants and convertible preferred stock, and their valuation metrics.

Risk Assessment

Risk Level: medium — BELITE BIO, INC shows moderate risk based on this filing. The filing is a 20-F, which is a standard annual report for foreign private issuers, indicating routine disclosure rather than immediate significant events. However, the nature of a biotech company in the pharmaceutical preparations sector inherently carries medium-to-high risk due to R&D, regulatory hurdles, and market competition.

Analyst Insight

Investors should review the detailed financial statements and risk factors within the 20-F to assess Belite Bio's financial position and future prospects, particularly concerning its research and development activities.

Key Numbers

Key Players & Entities

FAQ

When did BELITE BIO, INC file this 20-F?

BELITE BIO, INC filed this Foreign Annual Report (20-F) with the SEC on March 12, 2024.

What is a 20-F filing?

A 20-F is a annual report for foreign private issuers, equivalent to a 10-K but following international reporting standards. This particular 20-F was filed by BELITE BIO, INC (BLTE).

Where can I read the original 20-F filing from BELITE BIO, INC?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by BELITE BIO, INC.

What are the key takeaways from BELITE BIO, INC's 20-F?

BELITE BIO, INC filed this 20-F on March 12, 2024. Key takeaways: Belite Bio, Inc. filed its 20-F annual report for the fiscal year ending December 31, 2023.. The filing includes financial data and disclosures relevant to U.S. GAAP.. Key dates related to warrant valuations and stock offerings are noted, including June 2, 2023, and April 28, 2022..

Is BELITE BIO, INC a risky investment based on this filing?

Based on this 20-F, BELITE BIO, INC presents a moderate-risk profile. The filing is a 20-F, which is a standard annual report for foreign private issuers, indicating routine disclosure rather than immediate significant events. However, the nature of a biotech company in the pharmaceutical preparations sector inherently carries medium-to-high risk due to R&D, regulatory hurdles, and market competition.

What should investors do after reading BELITE BIO, INC's 20-F?

Investors should review the detailed financial statements and risk factors within the 20-F to assess Belite Bio's financial position and future prospects, particularly concerning its research and development activities. The overall sentiment from this filing is neutral.

Risk Factors

Key Dates

Filing Stats: 4,515 words · 18 min read · ~15 pages · Grade level 15.9 · Accepted 2024-03-11 21:05:28

Key Financial Figures

Filing Documents

Item 18

Item 17 Item 18 If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No Table of Contents TABLE OF CONTENTS PART I ITEM 1. Identity of Directors, Senior Management and Advisers 6 ITEM 2 . Offer Statistics and Expected Timetable 6 ITEM 3 . Key Information 6 ITEM 4. Information On the Company 75 ITEM 4A . Unresolved Staff Comments 132 ITEM 5 . Operating And Financial Review and Prospects 132 ITEM 6 . Directors, Senior Management and Employees 147 ITEM 7 . Major Shareholders and Related Party Transactions 159 ITEM 8. Financial Information 161 ITEM 9 . The Offer and Listing 162 ITEM 10 . Additional Information 162 ITEM 11 .

Quantitative And Qualitative Disclosures About Market Risk

Quantitative And Qualitative Disclosures About Market Risk 177 ITEM 12 .

Description Of Securities Other Than Equity Securities

Description Of Securities Other Than Equity Securities 177 PART II ITEM 13 . Defaults, Dividend Arrearages and Delinquencies 179 ITEM 14 . Material Modifications to The Rights of Security Holders and Use of Proceeds 179 ITEM 15 .

Controls And Procedures

Controls And Procedures 180 I TEM 16 A . Audit Committee Financial Expert 180

B

ITEM 16 B . Code of Ethics 181

C

ITEM 16 C . Principal Accountant Fees and Services 181

D

ITEM 16 D . Exemptions from the Listing Standards for Audit Committees 181

E

ITEM 16 E . Purchases of Equity Securities by the Issuer and Affiliated Purchasers 181

F

ITEM 16 F . Change in Registrant's Certifying Accountant 181

G

ITEM 16 G . Corporate Governance 182

H

ITEM 16 H . Mine Safety Disclosure 182 ITEM 16I. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 182 ITEM 16J. Insider Trading Policy 182 ITEM 16K. Cybersecurity 183 Part III ITEM 17 .

Financial Statements

Financial Statements 184 ITEM 18.

Financial Statements

Financial Statements 184 ITEM 19 . Exhibits 184 2 Table of Contents ABOUT THIS ANNUAL REPORT Unless otherwise indicated or the context otherwise requires, references in this annual report on Form 20-F (the " Annual Report ") to: " ADRs" are to the American depositary receipts that may evidence the ADSs; "ADSs" are to our American depositary shares, each of which represents one of our ordinary share; " AUD" are to the legal currency of Australia; " Belite," "we," "us," "our company," "Company," and "our" are to Belite Bio, Inc, a Cayman Islands exempted company with limited liability and its subsidiaries; "China" or the "PRC" are to the People's Republic of China, excluding, for the purposes of this Annual Report only, Hong Kong, Macau and Taiwan; "Exchange Act" are to the United States Securities Exchange Act of 1934, as amended; "EMA" are to European Medicines Agency; "FDA" are to U.S. Food and Drug Administration; "IND" are to Investigational New Drug Application; "Latest Practicable Date" are to March 11, 2024; "SEC" are to the United States Securities and Exchange Commission; "NMPA" are to National Medical Products Administration; "Securities Act" are to the Securities Act of 1933, as amended; " shares" or "ordinary shares" are to our ordinary shares, par value US$0.0001 per share; "TGA" are to Therapeutic Goods Administration of Australia; "US$," "U.S. dollars," "$," and "dollars" are to the legal currency of the United States; and " U.S. GAAP" are to the generally accepted accounting principles of the United States. Unless otherwise stated, all of our financial information presented in this Annual Report has been prepared in accordance with U.S. GAAP. Any discrepancies in any table between totals and sums of the amounts listed are due to rounding. Unless otherwise indicated, or the context otherwise requires, references in this Annual Report to financial and operational data for a particular year refer to the fiscal year of our co

IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS

ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS Not applicable.

OFFER STATISTICS AND EXPECTED TIMETABLE

ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE Not applicable.

KEY INFORMATION

ITEM 3. KEY INFORMATION A. [Reserved] B. Capitalization and Indebtedness Not applicable. 6 Table of Contents C. Reasons for the Offer and Use of Proceeds Not applicable. D. Risk Factors Careful consideration should be given to the following risk factors, in addition to the other information set forth in this Annual Report and in other documents that we file with the SEC, in evaluating our company and our business. Investing in our ADSs involves a high degree of risk. If any of the following risks actually occur, our business, financial condition, results of operations and future growth prospects could be materially and adversely affected. Risks Related to the Discovery, Development and Commercialization of Our Product Candidates Our business is highly dependent on the success of our lead product candidate, Tinlarebant (a/k/a LBS-008). If we are unable to develop, obtain marketing approval for or successfully commercialize Tinlarebant, either alone or through a collaboration, or if we experience significant delays in doing so, our business could be harmed. We currently have no products that are approved for commercial sale and may never be able to develop marketable products. Our business and future success depends in large part on our ability to develop, obtain regulatory approval for, and then successfully commercialize our lead product candidate, Tinlarebant. This may make an investment in our company riskier than similar companies that have multiple product candidates in active late-stage development that may be able to better sustain the failure of a lead product candidate. Further, if Tinlarebant does not obtain approval for the treatment of autosomal recessive Stargardt disease (STGD1), which is the initial indication that we are currently exploring, we will have spent substantial time and financial resources without receiving a return on investment. As a result, if Tinlarebant does not receive approval or fails to become profitable and receive

View Full Filing

View this 20-F filing on SEC EDGAR

View on Read The Filing